PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8

Pharmacogenet Genomics. 2013 Dec;23(12):721-8. doi: 10.1097/FPC.0b013e3283653b27.

Authors

Christina L Aquilante¹, Mikko Niemi, Li Gong, Russ B Altman, Teri E Klein

Affiliation

¹ aDepartment of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado Departments of bGenetics cBioengineering, Stanford University, Palo Alto, California, USA dDepartment of Clinical Pharmacology, University of Helsinki, HUSLAB, Helsinki University Central Hospital, Helsinki, Finland.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
Antimalarials / adverse effects
Antimalarials / pharmacokinetics
Antimalarials / pharmacology
Aryl Hydrocarbon Hydroxylases / antagonists & inhibitors
Aryl Hydrocarbon Hydroxylases / genetics*
Aryl Hydrocarbon Hydroxylases / metabolism*
Biotransformation
Chromosomes, Human, Pair 10
Cytochrome P-450 CYP2C8
Genetic Variation
Haplotypes
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / pharmacokinetics
Hypoglycemic Agents / pharmacology
Pharmacogenetics
Polymorphism, Single Nucleotide*

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antimalarials
Hypoglycemic Agents
Aryl Hydrocarbon Hydroxylases
CYP2C8 protein, human
Cytochrome P-450 CYP2C8

Grants and funding